Dray C: Difference between revisions
From Bioblast
No edit summary Β |
Beno Marija (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{Person}} | {{Person}} | ||
{{Labelingperson}} |
Revision as of 16:59, 26 March 2018
Name | , |
---|---|
Institution | |
Address | , |
City | |
State/Province | |
Country | |
Weblink | |
O2k-Network Lab | FR Toulouse Dray C |
Labels:
Publications
Published | Reference | |
---|---|---|
Vinel 2018 Nat Med | 2018 | Vinel C, Lukjanenko L, Batut A, Deleruyelle S, Pradere JP, Le Gonidec S, Dortignac A, Geoffre N, Pereira O, Karaz S, Lee U, Camus M, Chaoui K, Mouisel E, Bigot A, Mouly V, Vigneau M, Pagano AF, Chopard A, Pillard F, Guyonnet S, Cesari M, Burlet-Schiltz O, Pahor M, Feige JN, Vellas B, Valet P, Dray C (2018) The exerkine apelin reverses age-associated sarcopenia. Nat Med 24:1360-71. |
Valet 2015 US Patent | 2015 | Valet P, Dray C, Knauf C, Kunduzova O, Castan-Laurell I (2015) Pharmaceutical composition for use in the treatment of dysfunction associated with aging. US Patent US20150290286 A1. |
Attane 2012 Diabetes | 2012 | AttanΓ© C, Foussal C, Le Gonidec S, Benani A, Daviaud D, Wanecq E, GuzmΓ‘n-Ruiz R, Dray C, Bezaire V, Rancoule C, Kuba K, Ruiz-Gayo M, Levade T, Penninger J, Burcelin R, PΓ©nicaud L, Valet P, Castan-Laurell I (2012) Apelin treatment increases complete fatty acid oxidation, mitochondrial oxidative capacity, and biogenesis in muscle of insulin-resistant mice. Diabetes 61:310-20. |
Knauf 2008 Endocrinology | 2008 | Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget A, PΓ©nicaud L, Valet P, Burcelin R (2008) Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149:4768-77. |